Related Experiment Videos
Pathophysiologic role of myocardial apoptosis in post-infarction left ventricular remodeling
Antonio Abbate1, Giuseppe G L Biondi-Zoccai, Alfonso Baldi
1Institute of Cardiology, Catholic University of the Sacred Heart, Rome, Italy.
Insights
Apoptosis, or programmed cell death, drives heart failure after heart attacks by causing progressive myocyte loss. Reducing this cell death may improve patient outcomes and cardiac remodeling.
Area of Science:
- Cardiology
- Cell Biology
- Pathophysiology
Background:
- Left ventricular (LV) remodeling and heart failure (HF) are significant complications following acute myocardial infarction (AMI).
- Myocyte loss through apoptosis may contribute to progressive LV dilatation and dysfunction late after AMI.
Purpose of the Study:
- To review the role of apoptosis in cardiac remodeling post-AMI.
- To assess the clinical relevance, determinants, and mechanisms of myocardial apoptosis.
- To explore potential therapeutic implications for managing heart failure after myocardial infarction.
Main Methods:
- Review of animal experimental data.
- Analysis of observational studies in humans.
- Assessment of mechanisms including mitochondrial damage, Bcl-2/Bax balance, angiotensin II, and beta(1)-adrenergic stimulation.
Main Results:
- Mitochondrial damage and the Bcl-2 to Bax balance are key in ischemia-dependent apoptosis.
- Angiotensin II and beta(1)-adrenergic stimulation mediate receptor-dependent apoptosis.
- ACE-inhibitors and beta-blockers may reduce myocardial apoptosis, contributing to their benefits.
- Infarct-related artery patency influences myocardial apoptosis, supporting the 'open artery hypothesis'.
Conclusions:
- Myocardial apoptosis is a critical mechanism in post-AMI cardiac remodeling and heart failure.
- Understanding apoptosis pathways offers therapeutic targets for improving patient care after AMI.
- Maintaining infarct artery patency may reduce myocyte loss and enhance clinical outcomes.
Abstract:
Left ventricular (LV) remodeling and heart failure (HF) complicate acute myocardial infarction (AMI) even weeks to months after the initial insult. Apoptosis may represent an important pathophysiologic mechanism causing progressive myocardiocyte loss and LV dilatation even late after AMI. This review will discuss the role of apoptosis according to findings in animal experimental data and observational studies in humans in order to assess clinical relevance, determinants, and mechanisms of myocardial apoptosis and potential therapeutic implications. More complete definition of the impact of myocardiocyte loss on prognosis and of the mechanisms involved may lead to improved understanding of cardiac remodeling and possibly improved patients' care. Mitochondrial damage and bcl-2 to bax balance play a central role in ischemia-dependent apoptosis while angiotensin II and beta(1)-adrenergic-stimulation may be major causes of receptor-mediated apoptosis. Benefits due to treatment with ACE-inhibitors and beta-blockers appear to be in part due to reduced myocardial apoptosis. Moreover, infarct-related artery patency late after AMI may be a major determinant of myocardial apoptosis and clinical benefits deriving from an open artery late post AMI (the "open artery hypothesis") may be, at least in part, due to reduced myocardiocyte loss.